Medical Oncologist
Understanding your prognosis
Sorafenib Success Rate and Survival: — An Honest Look at the Numbers
When your oncologist mentions a median survival figure, it is easy to read it as a prediction about you. It is not. A median is a midpoint in a large group of people. Half lived longer. Understanding what the numbers mean — and what they cannot — helps you ask better questions.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- A median is a midpoint, not a ceiling — Half the people in any trial lived longer than the reported median. It is not a prediction for you specifically.
- Stable disease is a success — For sorafenib, slowing or stopping growth is the goal — not necessarily shrinking the tumour.
- Individual factors matter — Liver function, performance status, and tumour biology each influence how you personally respond.
- Honest numbers build trust — Knowing what the data shows — and where it cannot guide you — helps you make decisions with your care team.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Sorafenib is a targeted therapy that aims to slow tumour growth and extend survival in liver cancer, kidney cancer, and some thyroid cancers. Major trials show it can extend life compared to no active treatment. It does not eliminate the cancer. What any trial median means for you is a question your oncologist answers with your case in hand.
What does 'success' mean for a drug like sorafenib?
Sorafenib is not a drug that aims to eliminate the cancer. It aims to slow or stop the cancer from growing.
For most people on sorafenib, stable disease — the tumour neither shrinking nor growing — is the intended and meaningful outcome. The key trial question was not 'did the tumour disappear?' but 'how much longer did people live compared to those receiving no active treatment?'
The trials that established sorafenib, reported and cited by ASCO, ESMO, and NCCN, showed a survival benefit over placebo. That matters because before sorafenib, no systemic therapy had demonstrated that benefit in large randomised trials for advanced liver cancer.
What do these medical terms in my results mean?
- Median overall survival
- The point at which half the people in a trial had died and half were still alive. Half the group lived longer than this figure. It describes a population midpoint, not a personal forecast.
- Progression-free survival
- How long people went, on average, before the disease started growing again. It is often shorter than overall survival because people can receive further treatment after progression.
- Stable disease
- The tumour has neither shrunk enough to count as a response nor grown enough to count as progression. For sorafenib, this is a recognised and intended clinical benefit, not a failure.
- Response rate
- The proportion of patients whose tumour shrank by a defined amount. For sorafenib, this figure is low in most studies — stable disease is the more common and intended benefit.
- Hazard ratio
- A statistical comparison between two groups in a trial. A hazard ratio below 1.0 means the treatment group had a lower risk of death at any given time than the comparison group.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What does the median figure tell you — and what can it not?
A median is a population midpoint. Half the trial participants lived longer than the reported figure and half did not. It says nothing about which half you will be in.
Your position on that curve depends on factors no trial can account for individually: your liver function, performance status, how far the cancer has spread, how well you tolerate the drug, and the specific biology of your tumour.
This is not evasion. It is an honest description of what population data can and cannot do. Your oncologist's job is to bring your individual picture — your blood results, scan findings, and overall condition — alongside the trial data.
What should I ask my oncologist about my results?
- Ask whether your cancer type, stage, and liver function score match the patients enrolled in the main sorafenib trials.
- Ask what your performance status is and how it is expected to affect your response.
- Ask how response will be measured — which scans, on what schedule, and at what point a decision will be reviewed.
- Ask what the plan is if sorafenib stops controlling the disease.
- Ask whether there are clinical trials you may be eligible for alongside or after sorafenib.
- Ask for the goals of treatment to be stated clearly: is this intended to extend life, relieve symptoms, or both?
Did you know?
Sorafenib was the first systemic therapy to demonstrate a survival benefit over placebo in large randomised trials for advanced hepatocellular carcinoma. ESMO and ASCO guidelines describe this as a significant landmark because no systemic treatment had achieved that for advanced liver cancer before.
The median survival figures you may have read are anchored to that comparison — not a prediction, but evidence that the drug extended life against a world without it.
Source: ESMO Clinical Practice Guidelines for Hepatocellular Carcinoma; ASCO Sorafenib Clinical Evidence Summary
Explore 100 more Gastrointestinal & Liver Targeted Medicines topics
Drug Deep Dive: Sorafenib (Nexavar)
- Blood Pressure, Rash and Hair Thinning on Sorafenib
- Diarrhoea on Sorafenib: Controlling It Without Stopping Treatment
- Diet and Nutrition While on Sorafenib
- Drug, Food and Supplement Interactions With Sorafenib
- Fertility, Pregnancy and Contraception on Sorafenib
- Hand-Foot Skin Reaction on Sorafenib: Prevention From Day One
- How Does Sorafenib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Sorafenib Take to Work?
- How Long Will You Stay on Sorafenib?
- Sorafenib (Nexavar, Soranib): The Complete Patient Guide
- Sorafenib Myths: Dose Reduction, 'Last Resort' and Generic Quality
- Sorafenib Price in India: Brand, Generic and Monthly Cost
- Sorafenib Side Effects: The Complete List and Timeline
- Sorafenib Success Rate and Survival: An Honest Look at the Numbers
- Sorafenib With Cirrhosis: Why Child-Pugh Status Decides Eligibility
- Sorafenib With TACE and Other Liver-Directed Treatments
- Sorafenib in Elderly Patients and Those With Other Illnesses
- Sorafenib in Liver, Kidney and Thyroid Cancer: Three Different Uses
- Sorafenib vs Lenvatinib for Liver Cancer: Cost, Tolerability and Evidence
- Taking Sorafenib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Sorafenib
- When Sorafenib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Sorafenib? Liver, Kidney and Radioiodine-Refractory Thyroid Cancer
- Will Insurance or a Government Scheme Pay for Sorafenib?
- Work, Travel and Daily Life on Sorafenib
Drug Deep Dive: Bevacizumab (Avastin)
- Avastin vs Biosimilar Bevacizumab in India: Cost and Safety
- Bevacizumab (Avastin and biosimilars): The Complete Patient Guide
- Bevacizumab Infusion Day: Premedication, Duration and What to Expect
- Bevacizumab Myths: 'It Dissolves Tumours' and Other Misconceptions
- Bevacizumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Bevacizumab Side Effects: The Complete List and Timeline
- Bevacizumab Success Rate and Survival: An Honest Look at the Numbers
- Bevacizumab With Chemotherapy: Which Combinations and Why
- Bevacizumab in Elderly Patients and Those With Other Illnesses
- Bevacizumab in Eye Disease vs Cancer: Same Drug, Very Different Dose
- Bleeding, Bowel Perforation and Wound Healing Risks on Bevacizumab
- Diet and Nutrition While on Bevacizumab
- Drug, Food and Supplement Interactions With Bevacizumab
- Fertility, Pregnancy and Contraception on Bevacizumab
- High Blood Pressure on Bevacizumab: Monitoring and Treatment
- How Does Bevacizumab Work? The Anti-VEGF Angiogenesis Inhibitor Explained
- How Long Does Bevacizumab Take to Work?
- How Long Will You Stay on Bevacizumab?
- Protein in Your Urine on Bevacizumab: What the Report Means
- Surgery While on Bevacizumab: The 28-Day Rule
- Tests and Monitoring While You Are on Bevacizumab
- When Bevacizumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Bevacizumab? Colorectal, Lung, Ovarian, Cervical and Brain Cancer
- Will Insurance or a Government Scheme Pay for Bevacizumab?
- Work, Travel and Daily Life on Bevacizumab
Drug Deep Dive: Cetuximab (Erbitux)
- Cetuximab (Erbitux): The Complete Patient Guide
- Cetuximab Infusion Day: Premedication, Duration and What to Expect
- Cetuximab Infusion Reactions: Why the First Dose Is Given Slowly
- Cetuximab Myths: 'The Worse the Rash, the Better' and Other Half-Truths
- Cetuximab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Cetuximab Side Effects: The Complete List and Timeline
- Cetuximab Success Rate and Survival: An Honest Look at the Numbers
- Cetuximab With FOLFIRI, FOLFOX and Radiation
- Cetuximab in Colorectal vs Head and Neck Cancer: Different Roles
- Cetuximab in Elderly Patients and Those With Other Illnesses
- Cetuximab vs Bevacizumab in Colorectal Cancer: Which and When
- Diet and Nutrition While on Cetuximab
- Drug, Food and Supplement Interactions With Cetuximab
- Fertility, Pregnancy and Contraception on Cetuximab
- How Does Cetuximab Work? The Anti-EGFR Monoclonal Antibody Explained
- How Long Does Cetuximab Take to Work?
- How Long Will You Stay on Cetuximab?
- Low Magnesium on Cetuximab: Cramps, Fatigue and Monthly Testing
- Tests and Monitoring While You Are on Cetuximab
- The Cetuximab Rash: Severity, Treatment and Why It Predicts Response
- When Cetuximab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Cetuximab? RAS Wild-Type Colorectal Cancer and Head and Neck Cancer
- Why Cetuximab Only Works in RAS Wild-Type, Left-Sided Tumours
- Will Insurance or a Government Scheme Pay for Cetuximab?
- Work, Travel and Daily Life on Cetuximab
Drug Deep Dive: Lenvatinib (Lenvima)
- Blood Pressure Spikes on Lenvatinib: The Critical First Two Weeks
- Diarrhoea, Appetite Loss and Rapid Weight Drop on Lenvatinib
- Diet and Nutrition While on Lenvatinib
- Dose Reductions on Lenvatinib: Why Most Patients Need One
- Drug, Food and Supplement Interactions With Lenvatinib
- Fertility, Pregnancy and Contraception on Lenvatinib
- Hand-Foot Skin Reaction on Lenvatinib: Prevention and Relief
- How Does Lenvatinib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Lenvatinib Take to Work?
- How Long Will You Stay on Lenvatinib?
- Lenvatinib (Lenvima, Lenvanix): The Complete Patient Guide
- Lenvatinib Myths: Side Effects, Dose Cuts and 'Giving Up'
- Lenvatinib Price in India: Brand, Generic and Monthly Cost
- Lenvatinib Side Effects: The Complete List and Timeline
- Lenvatinib Success Rate and Survival: An Honest Look at the Numbers
- Lenvatinib With Immunotherapy: The Combination Explained
- Lenvatinib for Radioactive-Iodine-Refractory Thyroid Cancer
- Lenvatinib in Elderly Patients and Those With Other Illnesses
- Lenvatinib vs Sorafenib for Liver Cancer: Which Comes First?
- Taking Lenvatinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Lenvatinib
- When Lenvatinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Lenvatinib? Liver, Thyroid, Kidney and Endometrial Cancer
- Will Insurance or a Government Scheme Pay for Lenvatinib?
- Work, Travel and Daily Life on Lenvatinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does sorafenib cure liver cancer or kidney cancer?
For the majority of people, sorafenib is not intended to eliminate the cancer. It aims to slow or stop growth. In a proportion of patients, the disease stabilises for an extended period. A small number see measurable tumour shrinkage. Full clearance is not the expected outcome for most people on sorafenib, and the goals of treatment are better understood as extended stable disease rather than disappearance of the cancer.
Why won't my oncologist give me an exact survival figure?
Because no trial can provide one. Clinical trials give a median — the midpoint of a large group — not a prediction for any individual. Half the people in the trial lived longer than the reported figure and half did not. Your oncologist does not know in advance which half you will be in, and stating a number as though it applies to you specifically would be misleading. What they can explain is the overall survival benefit the drug showed and the factors in your own case that may influence your response.
What factors affect whether sorafenib will work for me?
The factors most closely linked to outcomes on sorafenib are your liver function score, your performance status, how far the cancer has spread, and any underlying conditions such as portal vein involvement in liver cancer. Your oncologist assesses these before recommending sorafenib and monitors them throughout treatment. None of these makes an outcome certain, but together they inform whether the likely benefit outweighs the side effects for you.
How long does sorafenib usually keep working?
This varies considerably between individuals, and there is no reliable way to predict it before starting. Published trials reported by ASCO and ESMO show a range around the median progression-free survival, with meaningful variation in both directions. Your oncologist will monitor you with imaging on a defined schedule and discuss the results at each assessment. If you want to understand the typical range from the main trials, ask your oncologist to walk you through the published figures for your specific cancer type.
What happens if sorafenib stops working?
If sorafenib stops controlling the disease, second-line options exist for several of the cancers it is used in. NCCN and ESMO guidelines include approved alternatives for both hepatocellular carcinoma and renal cell carcinoma after sorafenib. Which options apply depends on your cancer type, your condition at that point, and what has changed in your disease. Ask your oncologist about the second-line pathway now, before it becomes urgent — understanding what comes next reduces the anxiety of being on a drug that will not work indefinitely.
Is sorafenib given at CION, and how is treatment monitored?
Sorafenib is an oral tablet taken at home, not a hospital infusion, so it does not need to be administered at a centre. CION oncologists prescribe and monitor it, with regular blood tests and imaging to assess response and identify side effects early. Response-assessment scans such as PET-CT are coordinated with partner imaging centres. If you have questions about side effects or what your next scan will look for, your treating team at CION is the right first contact.